Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
YHOO : Sold half for a buck profit from the pre-market lows
Posted by: STRONGUS
In reply to: stockjob who wrote msg# 57037 Date:5/5/2008 8:14:15 AM
Post #of 57044
I am averaging up YHOO every 10 cents from 22.30 Already in nice green..LOL
There is no such thing as 'last chance' in stock market
YHOO : Sold half for a buck profit from the pre-market lows
Posted by: STRONGUS
In reply to: stockjob who wrote msg# 57037 Date:5/5/2008 8:14:15 AM
Post #of 57044
I am averaging up YHOO every 10 cents from 22.30 Already in nice green..LOL
here you go : http://money.cnn.com/data/premarket/nyse/
I am averaging up YHOO every 10 cents from 22.30 Already in nice green..LOL
Ballmer wanted to pay 33 dollars..I am paying just 22
I am averaging in; I am sure some positive spin will come later. LOL
Yeah..Too late to short now..may be we can play it for a bounce..lol..
Short yahoo & Buy Microsoft. The only problem is it sounds like a no brainer Normally Mr.Market doesn't let no brainers play out.
That is called being smart LOL
Cool I just went back and checked where we touched some raw nerves of each other. It is your arrogant approach. I am done here.
hey Tina, Got nothing against it Make a bundle.
I would rather play lotto than putting my money into an over hyped stock that is trading close to life time highs..
pinksheets stock are just for lotto money..there are so many bargains in big boards right now..I wouldn't even touch your junk stock with a 12 feet pole..
It is a pinkie..I wouldn't be surprised with any pinkie being a scam..
sounds lot better than the ones I saw with ZYNX.
thanks for the free tip..it is a pinkie..I wouldn't be surprised with any pinkie being a scam..
If you are that secure, what is the need to splash this message all over i-hub so many times.
Posted by: Rawnoc
In reply to: Rawnoc who wrote msg# 10248
Date:5/3/2008 4:58:24 PM
Post #of 10406
ZYNX -- been reporting exploding sales and net income. I think this stock has 5-10 bags written all over it. Anything under $2 will prove to be an absolute steal IMO. This is a medical device rental company (as such, reported an astonishing 90% in gross profit margins last quarter). ZYNX has a tiny float, small OS, tiny market cap, tiny debt levels, while fast growing sales and profits (with forecasts based on large increases in announced orders for more accelerated growth) with costs staying relatively flat. Due to the great success of their business model, they've recently juiced up the number of their sales staff, and I expected a further leap in sales & profits at a level that is a massive discount in relation to its currently tiny market cap. One thing that probably helps ZYNX a lot is that Medicare helps pay for a some of their customers.
PR in February confirms that they are planning to apply to uplist to the AMEX some very soon after the stock crosses $2/share.
board: http://www.investorshub.com/boards/board.asp?board_id=2696
dude, It is a typical pumper reaction to bring in another stock into the mix when we are talking about ZYNX.
You entire reaction shows a lot of insecurity. If you want to continue this discussion, we can do it on ZYNX board.
I bought it around 9 dollars range and already sitting on a nice profit. Thanks
I am aware of that and I wouldn't call it garbage
LOL. I was just proving information; not an opinion..interesting reaction from 'we don't drink koo-aid' crowd
My current top holdings are (dollar value wise) : SIGM OPXT CROC. I trade several big boards stock every day. It is interesting how people react when their money is on the line
I wouldn't call them garbage Good luck!
ZYNX : (From the latest 10-k) RISKS RELATED TO OUR BUSINESS
http://investorshub.advfn.com/boards/quotes.asp?ticker=zynx&qm_page=16124&qm_symbol=ZYNX
WE MAY BE UNABLE TO OBTAIN ADDITIONAL CAPITAL REQUIRED TO GROW OUR BUSINESS. WE MAY HAVE TO CURTAIL OUR BUSINESS IF WE CANNOT FIND ADEQUATE FUNDING.
Our ability to grow depends significantly on our ability to expand our operations through internal growth and by acquiring other companies or assets. This will require significant capital resources. We may need to seek additional capital from public or private equity or debt sources to fund our operating plans and respond to other contingencies such as:
- shortfalls in anticipated revenues or increases in expenses;
- the development of new products; or
- the expansion of our operations, including the recruitment of additional sales personnel.
- 18 -
During 2006, we sold shares of our common stock and related warrants in a non-public offering in order to provide funds for working capital and growth. We cannot be certain that we will be able to raise additional capital in the future on terms acceptable to us or at all. If alternative sources of financing are insufficient or unavailable, we may be required to modify our growth and operating plans in accordance with the extent of available financing. Any additional equity financing may involve substantial dilution to our then existing shareholders.
WE HAVE LIMITED LIQUIDITY BECAUSE OUR CASH REQUIREMENTS INCREASE AS OUR OPERATIONS EXPAND
Our limited liquidity is primarily a result of (a) the required high levels of consignment inventory that are standard in the electrotherapy industry, (b) the payment of commissions to salespersons based on sales or rentals prior to reimbursement for such transactions, (c) the high level of outstanding accounts receivable because of deferred payment practices of third party health payers, and (d) the delayed cost recovery inherent in rental transactions.
OUR POTENTIAL COMPETITORS COULD BE LARGER THAN US AND HAVE GREATER FINANCIAL AND OTHER RESOURCES THAN WE DO AND THOSE ADVANTAGES COULD MAKE IT DIFFICULT FOR US TO COMPETE WITH THEM.
Substantial competition may be expected in the future in the area of stroke rehabilitation that may directly compete with our NeuroMove product. Competitors to our products may have substantially greater financial, technical, marketing, and other resources. Competition could result in price reductions, fewer orders, reduced gross margins, and loss of market share. These companies may use standard or novel signal processing techniques to detect muscular movement and generate stimulation to such muscles. Other companies may develop rehabilitation products that perform better and/or are less expensive than our products. Our products are regulated by the U.S. Food and Drug Administration. Competitors may develop products that are substantially equivalent to our FDA approved products, thereby using our products as predicate devices to more quickly obtain FDA approval for their own. If overall demand for our products should decrease it could have a materially adverse affect on our operating results.
FAILURE TO KEEP PACE WITH THE LATEST TECHNOLOGICAL CHANGES COULD RESULT IN DECREASED REVENUES.
The market for our products is characterized by rapid change and technological improvements. Failure to respond in a timely and cost-effective way to these technological developments could result in serious harm to our business and operating results. We have derived, and we expect to continue to derive, a substantial portion of our revenues from creating products in the medical device industry. As a result, our success will depend, in part, on our ability to develop and market product offerings that respond in a timely manner to the technological advances of our competitors, evolving industry standards and changing client preferences.
WE ARE DEPENDENT ON REIMBURSEMENT FROM INSURANCE COMPANIES AND GOVERNMENT (MEDICARE AND MEDICAID) AGENCIES; CHANGES IN INSURANCE REIMBURSEMENT POLICIES COULD RESULT IN DECREASED OR DELAYED REVENUES
A large percentage of our revenues comes from insurance company and government agency reimbursement. Upon delivery of our products to our customers, we directly bill the customers' private insurance company or government payer for reimbursement. If the billed payers do not pay their bills on a timely basis or if they change their policies to exclude coverage for our products, we would experience delayed revenue recognition or a decline in our revenue as well as cash flow issues.
A MANUFACTURER'S INABILITY TO PRODUCE OUR GOODS ON TIME AND TO OUR SPECIFICATIONS COULD RESULT IN LOST REVENUE.
Third-party manufacturers assemble and manufacture to our specifications most of our products. The inability of a manufacturer to ship orders of our products in a timely manner or to meet our quality standards could cause us to miss the delivery date requirements of our customers for those items, which could result in cancellation of orders, refusal to accept deliveries or a reduction in purchase prices, any of which could have a material adverse affect on our revenues. Because of the timing and seriousness of our business, and the medical device industry in particular, the dates on which customers need and require shipments of products from us are critical. Further, because quality is a leading factor when customers, doctors, health insurance providers and distributors accept or reject goods, any decline in quality by our third-party manufacturers could be detrimental not only to a particular order, but also to our future relationship with that particular customer.
- 19 -
iF WE NEED TO REPLACE MANUFACTURERS, OUR EXPENSES COULD INCREASE RESULTING IN SMALLER PROFIT MARGINS.
We compete with other companies for the production capacity of our manufacturers and import quota capacity. Some of these competitors have greater financial and other resources than we have, and thus may have an advantage in the competition for production and import quota capacity. If we experience a significant increase in demand, or if we need to replace an existing manufacturer, we may have to expand our third-party manufacturing capacity. We cannot assure that this additional capacity will be available when required on terms that are acceptable to us or similar to existing terms, which we have with our manufacturers, either from a production standpoint or a financial standpoint. We enter into a number of purchase order commitments specifying a time for delivery, method of payment, design and quality specifications and other standard industry provisions, but do not have long-term contracts with any manufacturer. None of the manufacturers we use produces our products exclusively.
Should we be forced to replace one or more of our manufacturers, we may experience increased costs or an adverse operational impact due to delays in distribution and delivery of our products to our customers, which could cause us to lose customers or lose revenue because of late shipments.
OUR BUSINESS IS EXPOSED TO DOMESTIC INTEREST RATES AND FOREIGN CURRENCY FLUCTUATIONS; NEGATIVE CHANGES IN EXCHANGE RATES COULD RESULT IN GREATER COSTS.
Most of Zynex's revenue, expenses, and capital spending have been transacted in US dollars. Zynex's exposure to market risk for changes in interest rates relate primarily to Zynex's cash and cash equivalent balances, marketable securities, investment in sales-type leases, and loan agreements. The majority of Zynex's investments, if any, may be in short-term instruments and therefore subject to fluctuations in US interest rates. Due to the nature of such short-term investments, we cannot assure that this will not have a material adverse impact on our financial condition and results of operations.
IF WE ARE UNABLE TO RETAIN THE SERVICES OF MR. SANDGAARD OR IF WE ARE UNABLE TO SUCCESSFULLY RECRUIT QUALIFIED MANAGERIAL AND SALES PERSONNEL HAVING EXPERIENCE IN OUR BUSINESS, WE MAY NOT BE ABLE TO CONTINUE OUR OPERATIONS.
Our success depends to a significant extent upon the continued service of Mr. Thomas Sandgaard, our Chief Executive Officer and currently sole director. Loss of the services of Mr. Sandgaard could have a material adverse effect on our growth, revenues, and prospective business. We do not maintain key-man insurance on the life of Mr. Sandgaard. In addition, in order to successfully implement and manage our business plan, we will be dependent upon, among other things, successfully recruiting qualified managerial and sales personnel having experience in business. Competition for qualified individuals is intense. There can be no assurance that we will be able to find, attract and retain qualified new employees and retain existing employees.
HOSPITALS AND CLINICIANS MAY NOT BUY, PRESCRIBE OR USE OUR PRODUCTS IN SUFFICIENT NUMBERS, WHICH COULD RESULT IN DECREASED REVENUES.
Hospitals and clinicians may not accept the NeuroMove NM900, IF8000, IF8100, TruWave or E-Wave products as effective, reliable, and cost-effective. Factors that could prevent such institutional customer acceptance include:
- If customers conclude that the costs of these products exceed the cost savings associated with the use of these products;
- If customers are financially unable to purchase these products;
- If adverse patient events occur with the use of these products, generating adverse publicity;
- If we lack adequate resources to provide sufficient education and training to Zynex's customers; and
- If frequent product malfunctions occur, leading clinicians to believe that the products are unreliable.
If any of these or other factors results in the non-use or non-purchase of our products, we will have reduced revenues and may not be able to fully fund operations.
- 20 -
AS A RESULT OF BEING IN THE MEDICAL DEVICE INDUSTRY, WE NEED TO MAINTAIN SUBSTANTIAL INSURANCE COVERAGE, WHICH COULD BECOME VERY EXPENSIVE OR HAVE LIMITED AVAILABILITY.
Our marketing and sale of products and services related to the medical device field creates an inherent risk of claims for liability. As a result, we carry product liability insurance with an aggregate limit of $5,000,000 and $2,000,000 per occurrence and will continue to maintain insurance in amounts we consider adequate to protect us from claims. We cannot, however, be assured to have resources sufficient to satisfy liability claims in excess of policy limits if required to do so. Also, there is no assurance that our insurance provider will not drop our insurance or that our insurance rates will not substantially rise in the future, resulting in increased costs to us or forcing us to either pay higher premiums or reduce our coverage amounts, which would result in increased liability to claims.
OUR FUTURE DEPENDS UPON OBTAINING REGULATORY APPROVAL OF ANY NEW PRODUCTS AND/OR MANUFACTURING OPERATIONS WE DEVELOP; FAILURE TO OBTAIN REGULATORY APPROVAL COULD RESULT IN INCREASED COSTS AND LOST REVENUE.
Before marketing any new products, we will need to complete one or more clinical investigations of each product. There can be no assurance that the results of such clinical investigations will be favorable to us. We may not know the results of any study, favorable or unfavorable to us, until after the study has been completed. Such data must be submitted to the FDA as part of any regulatory filing seeking approval to market the product. Even if the results are favorable, the FDA may dispute the claims of safety, efficacy, or clinical utility and not allow the product to be marketed. The sale price of the product may not be enough to recoup the amount of our investment in conducting the investigative studies.
WE MAY INCUR SUBSTANTIAL EXPENSES AND MAY INCUR LOSSES.
The area of medical device research is subject to rapid and significant technological changes. Developments and advances in the medical industry by either competitors or neutral parties can affect our business in either a positive or negative manner. Developments and changes in technology that are favorable to us may significantly advance the potential of our research while developments and advances in research methods outside of the methods we are using may severely hinder, or halt completely our development.
We are a small company in terms of employees, technical and research resources and capital. We expect to have research and development and significant sales and marketing, and general and administrative expenses for several years. These amounts may be expended before any commensurate incremental revenue from these efforts may be obtained. These factors could hinder our ability to meet changes in the medical industry as rapidly or effectively as competitors with more resources.
WE MAY BE UNABLE TO PROTECT OUR TRADEMARKS, TRADE SECRETS AND OTHER INTELLECTUAL PROPERTY RIGHTS THAT ARE IMPORTANT TO OUR BUSINESS.
We regard our trademarks, particularly our NeuroMove trademark which is registered in the United States and the European Union, our trade secrets and other intellectual property as an integral component of our success. We rely on trademark law, patents, and trade secret protection and confidentiality agreements with employees, customers, partners and others to protect our intellectual property. Effective trademark and trade secret protection may not be available in every country in which our products are available. We cannot be certain that we have taken adequate steps to protect our intellectual property, especially in countries where the laws may not protect our rights as fully as in the United States. In addition, if our third-party confidentiality agreements are breached there may not be an adequate remedy available to us. If our trade secrets become publicly known, we may lose our competitive position.
- 21 -
SUBSTANTIAL COSTS COULD BE INCURRED DEFENDING AGAINST CLAIMS OF INFRINGEMENT.
Other companies, including competitors, may obtain patents or other proprietary rights that would limit, interfere with, or otherwise circumscribe Zynex's ability to make, use, or sell products. Should there be a successful claim of infringement against us and if we could not license the alleged infringed technology, business and operating results could be adversely affected. There has been substantial litigation regarding patent and other intellectual property rights in the medical device industry. The validity and breadth of claims covered in medical technology patents involve complex legal and factual questions for which important legal principles remain unresolved. Any litigation claims against us, independent of their validity, may result in substantial costs and the diversion of resources with no assurance of success. Intellectual property claims could cause us to:
- Cease selling, incorporating, or using products that incorporate the challenged intellectual property,
- Obtain a license from the holder of the infringed intellectual property right on reasonable terms, if at all, and
- Re-design Zynex's products incorporating the infringed intellectual property.
COMMERCIALIZATION OF OUR PRODUCTS COULD FAIL IF IMPLEMENTATION OF OUR SALES AND MARKETING STRATEGY IS UNSUCCESSFUL.
A significant sales and marketing effort may be necessary to achieve the level of market awareness and sales needed to achieve our financial projections. To increase sales and rental of our products we may utilize some or all of the following strategies in the future:
- Contract with, hire and train sales and clinical specialists;
- Build a larger direct sales force;
- Manage geographically dispersed operations;
- Explore potential reseller and original equipment manufacturer (OEM) relationships and assure that reseller and OEMs provide appropriate educational and technical support;
- Promote frequent product use to increase sales of consumables; and
- Enter into relationships with well-established distributors in foreign markets.
These strategies could be costly and may impact our operating results. If these strategies do not generate increased revenue, the result will be increased operating expenses greater than the revenue, resulting in a reduction of net income or even a net loss.
OUR BUSINESS COULD BE ADVERSELY AFFECTED BY RELIANCE ON SOLE SUPPLIERS.
Notwithstanding our current multiple supplier approach, in the future certain essential product components may be supplied by separate sole, or a limited group of, suppliers. Most of our products and components are purchased through purchase orders rather than through long term supply agreements and large volumes of inventory may not be maintained. There may be shortages and delays in obtaining certain product components. Disruption of the supply or inventory of components could result in a significant increase in the costs of these components or could result in an inability to meet the demand for our products. In addition, if a change in the manufacturer of a key component is required, qualification of a new supplier may result in delays and additional expenses in meeting customer demand for products. These factors could affect our revenues and ability to retain our experienced sales force.
- 22 -
WE MAY NOT BE ABLE TO OBTAIN CLEARANCE OF A 510 (K) NOTIFICATION OR APPROVAL OF A PRE-MARKET APPROVAL APPLICATION WITH RESPECT TO ANY PRODUCTS ON A TIMELY BASIS, IF AT ALL.
If timely FDA clearance or approval of new products is not obtained, our business could be materially adversely affected. Clearance of a 510 (k) notification may also be required before marketing certain previously marketed products, which have been modified after they have been cleared. Company personnel currently believe that certain planned enhancements to our current products will not necessitate the filing of a new 510(k) notification. Should the FDA so require, the filing of a new 510(k) notification for the modification of the product may be required prior to marketing any modified devices.
THE FDA ALSO REQUIRES ADHERENCE TO GOOD MANUFACTURING PRACTICES (GMP) REGULATIONS, WHICH INCLUDE PRODUCTION DESIGN CONTROLS, TESTING, QUALITY CONTROL, STORAGE AND DOCUMENTATION PROCEDURES.
To determine whether adequate compliance has been achieved, the FDA may inspect our facilities at any time. Such compliance can be difficult and costly to achieve. Our compliance status may change due to future changes in, or interpretations of, FDA regulations or other regulatory agencies. Such changes may result in the FDA withdrawing marketing clearance or requiring product recall. In addition, any changes or modifications to a device or its intended use may require us to reassess compliance with Good Manufacturing Practices guidelines, potentially interrupting the marketing and sale of products. Failure to comply with regulations could result in enforceable actions, including product seizures, product recalls, withdrawal of clearances or approvals, and civil and criminal penalties.
OUR BUSINESS IS SUBJECT TO EXTENSIVE GOVERNMENT REGULATION, THE FAILURE TO COMPLY WITH WHICH COULD RESULT IN SIGNIFICANT PENALTIES.
Numerous state and federal government agencies extensively regulate the manufacturing, packaging, labeling, advertising, promotion, distribution and sale of our products. Our failure or inability to comply with applicable laws and governmental regulations may result in civil and criminal penalties, which we are unable to pay or may cause us to curtail or cease operations. We must also expend resources from time to time to comply with newly adopted regulations, as well as changes in existing regulations. If we fail to comply with these regulations, we could be subject to disciplinary actions or administrative enforcement actions.
CHANGES IN COVERAGE AND REIMBURSEMENT POLICIES FOR OUR PRODUCTS BY MEDICARE OR REDUCTIONS IN REIMBURSEMENT RATES FOR OUR PRODUCTS COULD ADVERSELY AFFECT OUR BUSINESS AND RESULTS OF OPERATIONS.
In the United States, our products are prescribed by physicians for their patients. Based on the prescription, which Zynex considers an order, we submit a claim for payment directly to third party payers such as private commercial insurance carriers, Medicare or Medicaid and others as appropriate and the payer reimburses Zynex directly. Federal and state statutes, rules or other regulatory measures that restrict coverage of our products or reimbursement rates could have an adverse effect on our ability to sell or rent our products or cause physical therapists and physicians to dispense and prescribe alternative, lower-cost products.
With the passage of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or Medicare Modernization Act, a number of changes have been mandated to the Medicare payment methodology and conditions for coverage of our durable medical equipment, including our TENS and NMES devices. These changes include a freeze in payments for our durable medical equipment from 2004 through 2008, competitive bidding requirements, and new clinical conditions for payment and quality standards. Although these changes affect our products generally, specific products may be more or less affected by the Medicare Modernization Act's provisions.
- 23 -
Certain off-the-shelf durable medical equipment (DME), including TENS devices, may become subject to competitive bidding, in order to reduce costs and reimbursements to DME suppliers. Under competitive bidding, if implemented, Medicare will change its approach to reimbursing certain items and services covered by Medicare from the current fee schedule amount to an amount established through a bidding process between the government and suppliers. Competitive bidding may reduce the number of suppliers providing certain items and services to Medicare beneficiaries and the amounts paid for such items and services. Also, Medicare payments in regions not subject to competitive bidding may be reduced using payment information from regions subject to competitive bidding. Any payment reductions or the inclusion of certain of our products in competitive bidding, in addition to the other changes to Medicare reimbursement and standards contained in the Medicare Modernization Act, could have a material adverse effect on our results of operations.
In addition, in 2003, the Centers for Medicare and Medicaid Services, or CMS made effective an interim final regulation implementing "inherent reasonableness" authority, which allows adjustments to payment amounts for certain items and services covered by Medicare when the existing payment amount is determined to be "grossly excessive" or "grossly deficient " The regulation lists factors that may be used to determine whether an existing reimbursement rate is grossly excessive or grossly deficient and to determine what is a realistic and equitable payment amount. The regulation remains in effect after the enactment of the Medicare Modernization Act, although the new legislation precludes the use of inherent reasonableness authority for payment amounts established under competitive bidding. Medicare and Medicaid accounted for approximately 5% of our total sales and rental income for 2006. When using the inherent reasonableness authority, CMS may reduce reimbursement levels for certain of our products, which could have a material adverse effect on our results of operations.
OUR PRODUCTS ARE SUBJECT TO RECALL EVEN AFTER RECEIVING FDA OR FOREIGN CLEARANCE OR APPROVAL, WHICH WOULD HARM OUR REPUTATION AND BUSINESS.
We are subject to medical device reporting regulations that require us to report to the FDA or respective governmental authorities in other countries if our products cause or contribute to a death or serious injury or malfunction in a way that would be reasonably likely to contribute to death or serious injury if the malfunction were to recur. The FDA and similar governmental authorities in other countries have the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacturing. A government mandated or voluntary recall by us could occur as a result of component failures, manufacturing errors or design defects, including defects in labeling. Any recall would divert managerial and financial resources and could harm our reputation with customers. We cannot assure you that we will not have product recalls in the future or that such recalls would not have a material adverse effect on our business. We have not undertaken any voluntary or involuntary recalls to date.
OUR PRINCIPAL OFFICER AND DIRECTOR OWNS A CONTROLLING INTEREST IN OUR VOTING STOCK AND INVESTORS WILL NOT HAVE ANY VOICE IN OUR MANAGEMENT.
Our Chief Executive officer and current sole director, Thomas Sandgaard, beneficially owns approximately 63.0% of our outstanding common stock as of April 15, 2008. As a result, Mr. Sandgaard has the ability to control substantially all matters submitted to our stockholders for approval, including:
- Election of our board of directors;
- Removal of any of our directors;
- Amendment of our certificate of incorporation or bylaws; and
- Adoption of measures that could delay or prevent a change in control or impede a merger, takeover or other business combination involving us.
As a result of his ownership and position, Mr. Sandgaard is able to influence all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. In addition, sales of significant amounts of shares held by Mr. Sandgaard, or the prospect of these sales, could adversely affect the market price of our common stock. Mr. Sandgaard's stock ownership may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of us, which in turn could reduce our stock price or prevent our stockholders from realizing a premium over our stock price.
- 24 -
RISKS RELATING TO OUR COMMON STOCK
OUR COMMON STOCK IS SUBJECT TO THE "PENNY STOCK" RULES OF THE SEC AND THE TRADING MARKET IN OUR SECURITIES IS LIMITED, WHICH MAKES TRANSACTIONS IN OUR STOCK CUMBERSOME AND MAY REDUCE THE VALUE OF AN INVESTMENT IN OUR STOCK.
Since our common stock is not listed or quoted on any stock exchange and no other exemptions currently apply, trading in our common stock on the Over-The-Counter Bulletin Board is subject to the "penny stock" rules of the SEC. These rules require, among other things, that any broker engaging in a transaction in our securities provide its customers with a risk disclosure document, disclosure of market quotations, if any, disclosure of the compensation of the broker and its salespersons in the transaction, and monthly account statements showing the market values of our securities held in the customer's accounts. The brokers must provide bid and offer quotations and compensation information before making any purchase or sale of a penny stock and also provide this information in the customer's confirmation. Generally, brokers may be less willing to execute transactions in securities subject to the "penny stock" rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our stock.
The company isn't the one dumping imo. Why would they buy back for 5 dollars only to dump at 10 cents range?? It doesn't make sense. There was hardly any volume to dump all the 42 million they bought back. It will have a big run soon imo. I am not giving up here, risi.
eik, You are asking way too many questions to lee for paying 19 cents for that stock just kidding..lol..FWIW, I am averaging into LUMC.
That was a great quote!
it was quicksand at 4 cents and now pre gold rush at 9 cents Just that we bought the gold cheaper..lol..
Nice to hear from you I know our bullish case has been stated many times here and most longs decided to ignore the rantings of a select few so far. I think the time has arrived for longs to stand up and get counted. I am confident that this stock will reward us for our patience. I see some of the competitors are going out of business. This can only be good for the survivors like ARSC.
Supra, I am going to give you only one hint There is money to be made on ARSC by going long right now. Don't come back to me saying longs said that before at higher prices. There is nothing new in that argument. Unless some one hates making money, the best way to play this right now is to go long. You wanna bet?? This is not invitation to you to buy the shares. I am providing my counter point to your 'doom & gloom' prediction. Let us see who prevails. The company is getting ready to hit back with vengeance. Watch out..
Stop the supply + Put the news + Screw the shorts = Strongus run
The only problem is lot of what they are 'hearing' is insider information. SEC will love this explosive stuff..lol
Just like the clock works Wondering why he never picked it up in bottombuster list at 4 cents..lol..
Not really in our context. I hate to clutter this forum. We can do this via Private messages.
Friends, ARSC.OB is getting ready to reverse the long downtrend. ARSC closed at 1.8 cents. Keep an eye on it Have a nice weekend, every one.
I am in LUMC big time Added a few times in the last 2 days.. Thats some solid dd there, lee. I haven't posted much on this forum for a while. May be it is time to bring it back to life
Posted by: leebret
In reply to: None Date:5/3/2008 10:19:43 AM
Post #of 390
Things that have changed (vs) Things that haven't.
Things that changed.
1) On March 31st 2008 Luminent announces with a pr the proposed restructuring the stock opens @ 65 and hits a low of .55 and closes @.61 on 890,400 shares
2) The zacks article on April 14th gave a .30 price target and nothing to really back up their position.....link below; Stock drops from a high of .52 and closes @.44 on 1,214,000 shares.
http://www.zacks.com/blog/post_detail.html?t=12318
3) On April 28th 2008 the NYSE puts out a pr of its own saying they would delist the company on Friday, May 2nd. Stock opens on the (28th) @ .38 and closes @ .37 on low volume of 231,600 shares and as the week progresses to Thursday (May 1st) the day before the delisting we open @.25 and close @.22 on heavy volume of 5,437,700 shares as institutions liquidate their positions.
NEW YORK, April 28, 2008 – NYSE Regulation, Inc. (“NYSE Regulation”) announced today that it determined that the common stock of Luminent Mortgage Capital, Inc. (the “Company”) – ticker symbol LUM - should be suspended prior to the opening on Friday, May 2, 2008.
The decision was reached in view of the fact that the Company has fallen below the New York Stock Exchange’s (“NYSE”) continued listing standard regarding average share price over a consecutive 30 trading-day period of not less than $1.00. In addition, the market capitalization of the Company’s common stock recently has also fallen below the NYSE’s continued listing standard regarding average global market capitalization over a consecutive 30 trading day period of not less than $25 million, which is the minimum threshold for listing.
4) We start trading the OTC exchange with all the chaos of ticker symbol change, no streamer exc. We open @.21 hit a low of .15 and close @.19 with heavy volume of 2,539,200 shares traded. With those who got shocked, running from their positions.
Now onto the things that haven't changed. This is the part that irritates the doom and gloomers who claim at every-turn that "I" told you so...."Look at me and what I said, ain't I brilliant"? Now while I will agree they have visual evidence that the share price has changed and they temporarily have crystal balls that seem to work.
I'm so sorry to disappoint them when I say ...........Nothing has changed and now I'll run down a list of things that we have no need of a crystal ball to enhance our positions to remain long.
THINGS THAT HAVEN'T CHANGED;
1) On April 22nd I reported the new short numbers. By April 15th they had covered almost 4 million shares of the 11 million short over a 45 day period. I'm sure the new period between April 15th and April 30th those numbers went even lower. Last short numbers reported on April 15th stood @ approximately 7 million.
Even though the short numbers haven't boosted the share price they have continued to cover and we have the evidence to prove it. Assuming they covered as many as 2 million in the latest period, they still need 5 million more. The four events above helped them in their quest to cover while not raising the price and I don't think there is anyone that would disagree with that. So there is no need for anyone to point out the lack of the "so called short squeeze" hasn't happened. It's obvious, we know, and we understand why we haven't got one! Now do you get it? No need for a crystal ball to explain it, hey?
2) Since August of 2007 when everything collapsed and expectations were they would declare bankruptcy, the doors remain open and Luminent remains in business.
3) Has anything changed since the release of their 10k (for the year 2007) on March 28th 2008? They took another massive write down and remain in business as of May the 3rd.
4) In December we know that Arco upped the extended line of credit to Luminent too $190 million dollars.
5) At the end of Dec we know they had $45 million of undistributed income to shareholders;
As of December 31, 2007, we estimate that we had approximately $45.0 million of undistributed REIT taxable income
6) We know that as of Dec 31st 2007 they had over 4 billion of loans on the books;
For the near-term, we believe we can take advantage of our existing resources to absorb CRM business without significant increases in expenses as our own whole portfolio has decreased from $5.9 billion as of July 2007 to $4.2 billion as of December 31, 2007 primarily due to prepayments.
7) We know that the markets have stabilized since last August and with the latest Fed moves, it has pumped much needed liquidity back into the markets.
8) We know that the recent cut in interest rates has added significantly to Luminent's advantage.
9) We know of no additional margin calls since the last reporting period.
10) We can assume that the first & second quarter numbers will be much better than the 3rd and 4th quarters of 2007.
11) We know that in addition to the 45 million of undistributed income through Dec 2007 they will also have the 1st and 2nd quarters income to distribute as well.
12) We know that they will be paying out a one time dividend of cash and stock at some point in this process.
13) We know that Arco has been steadfast in their continued support of Luminent, with cash and board-member guidance.
14) We know that those short this stock will want to cover their positions long before (if possible) any dividend is announced. We have the evidence!
15) We know they have a plan of action under the new LLC to become diversified and already have a new partner in one venture.
16) We know that the current market cap in no way reflects the current value of the company even with the negative events of late.
17) We know that one day they will up-list the stock.
18) We know the silence is do to pending lawsuits and the litigious society we live in.
19) We know that by the end of June we will have several pr's about the dividend payouts and much more up-to-date financial information to properly value Luminent.
20) Twenty is for the Naysayer's.
We know that there are many on the sidelines wishing, praying, hoping, for this to fall much further. We know they want it to fall so they can jump in for a quick trade. We know that they are vicious and unrelenting in there pursuit of all the negatives. We know that they will joyfully proclaim that they jumped in and made a quick trade. They will stop at nothing to disrupt any logical long term view and remind everyone how far the price has fallen. They are hanging around in the hopes of jumping in quickly on any positive news. Some enjoy the art of inflicting pain on anyone's loses and how superior it makes them feel when they can ridicule and degrade others.
I could have made more points on "Things that haven't changed" and anyone that would like to add more is certainly welcome to do so. I don't invest with my heart, I invest with my head and the knowledge that I have attained. I have a large investment and the things that haven't changed is the reason I share these things and hold my investment
There is no THE bottom in stock market. Every cycle brings in its own top and bottom. I know you were calling for 3 cents this time. LOL. The current move got nothing to do with the fundamentals. It is due to NITE pushing all buttons to take the stock up. Unless we get some news of substance, the rally will fail. Eventually the believers will win if the story is right. I think it is.
It is nice to see bullishness returning finally. It was so dark when HMGP was trading 4 cents and no one had guts to say a single positive thing. I see i-hub slowly catching up the run and HMGP showing up on many radars. The momo pumpers will join the party in the last leg as usual Any one who nailed the bottom on this one is a genius. Good luck to all friends here!
ARSC : I was going to let it go but a few clarifications may be in order here.
So first things first.
#1) Comparison to MCEL makes no sense because MCEL is neck deep in debt. They didn't get any funding where as ARSC already did.
#2) The recent increase in the O/S was due to issuance of shares as collateral for the closing of the funding (this is according to the company). These are restricted shares and not going to hit the market any time soon.
#3) They already sealed the deal for 2 million dollars funding and their technology licensee (Ohio univ) already got 1 million dollars in grant.
#4) The market cap is less than 4 million dollars. Considering #3, this is actually being valued at just 1 cent share price.
#5)Most longs who believe in the long term potential don't really care if this is at 2 cents or 3 cents today.
#6) Last but not the least, 'a short killer' is on the way and
it is time for a Strongus rally
Yes, eik! Current Results of the Shares Buy-Back Program
North West Oil Group
MOSCOW--(Marketwire - July 31, 2007) - NWOG Inc. (PINKSHEETS: NWOG) continues buying back shares. Within the last two months 18 million shares have been bought back. The overall amount of shares that have been bought back since the beginning of the present year constitutes 48 million. The shares buy-back program will be carried out until the end of the current year.
About North West Oil Group (formerly Nord Oil International): North West Oil Group is a non-reporting, publicly traded Oil & Gas company trading under the ticker symbol NWOG on the U.S. Pinksheets market.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.
Contact:
Evgeniya Popova
North West Oil Group
Tel: +7 495 621 11 15
E-Mail: jane@szng.ru
Web: http://www.szng.ru
Click here to see all recent news from this company